Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 07, 2022

BUY
$0.16 - $100.0 $19,558 - $12.2 Million
122,242 Added 72.66%
290,480 $45,000
Q2 2022

Aug 09, 2022

BUY
$0.2 - $0.5 $33,647 - $84,119
168,238 New
168,238 $70,000
Q1 2022

May 17, 2022

SELL
$0.41 - $0.63 $73,644 - $113,161
-179,621 Closed
0 $0
Q4 2021

Feb 17, 2022

BUY
$0.57 - $1.29 $102,383 - $231,711
179,621 New
179,621 $105,000
Q3 2021

Nov 12, 2021

SELL
$1.11 - $1.7 $162,236 - $248,470
-146,159 Closed
0 $0
Q2 2021

Sep 17, 2021

BUY
$1.46 - $2.25 $213,392 - $328,857
146,159 New
146,159 $247,000
Q1 2021

May 19, 2021

SELL
$1.77 - $2.93 $34,769 - $57,556
-19,644 Closed
0 $0
Q4 2020

Feb 24, 2021

SELL
$2.13 - $3.26 $219,581 - $336,073
-103,090 Reduced 83.99%
19,644 $42,000
Q3 2020

Dec 11, 2020

BUY
$1.53 - $3.13 $74,373 - $152,149
48,610 Added 65.58%
122,734 $367,000
Q2 2020

Aug 07, 2020

BUY
$0.48 - $1.75 $35,579 - $129,717
74,124 New
74,124 $111,000
Q3 2019

Nov 20, 2019

SELL
$0.81 - $1.06 $36,112 - $47,257
-44,583 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$0.94 - $1.6 $22,622 - $38,505
24,066 Added 117.3%
44,583 $46,000
Q1 2019

Apr 12, 2019

SELL
$0.51 - $1.88 $86,653 - $319,427
-169,908 Reduced 89.23%
20,517 $32,000
Q4 2018

Jan 16, 2019

BUY
$0.39 - $3.47 $74,265 - $660,774
190,425 New
190,425 $82,000
Q1 2018

May 14, 2018

SELL
$1.51 - $2.06 $289,468 - $394,904
-191,701 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$1.4 - $2.6 $252,076 - $468,143
180,055 Added 1546.07%
191,701 $307,000
Q3 2017

Nov 15, 2017

BUY
$2.22 - $2.79 $25,854 - $32,492
11,646
11,646 $0

About TREVENA INC


  • Ticker TRVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 173,680,992
  • Market Cap $292M
  • Description
  • Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...
More about TRVN
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.